» Articles » PMID: 19682280

Identification of Direct Transcriptional Targets of (V600E)BRAF/MEK Signalling in Melanoma

Overview
Date 2009 Aug 18
PMID 19682280
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Oncogenic mutations in BRAF are common in melanoma and drive constitutive activation of the MEK/ERK pathway. To elucidate the transcriptional events downstream of (V600E)BRAF/MEK signalling we performed gene expression profiling of A375 melanoma cells treated with potent and selective inhibitors of (V600E)BRAF and MEK (PLX4720 and PD184352 respectively). Using a stringent Bayesian approach, we identified 69 transcripts that appear to be direct transcriptional targets of this pathway and whose expression changed after 6 h of pathway inhibition. We also identified several additional genes whose expression changed after 24 h of pathway inhibition and which are likely to be indirect transcriptional targets of the pathway. Several of these were confirmed by demonstrating their expression to be similarly regulated when BRAF was depleted using RNA interference, and by using qRT-PCR in other BRAF mutated melanoma lines. Many of these genes are transcription factors and feedback inhibitors of the ERK pathway and are also regulated by MEK signalling in NRAS mutant cells. This study provides a basis for understanding the molecular processes that are regulated by (V600E)BRAF/MEK signalling in melanoma cells.

Citing Articles

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.

Delyon J, Becherirat S, Roger A, Bernard-Cacciarella M, Reger De Moura C, Louveau B Cell Commun Signal. 2024; 22(1):559.

PMID: 39574163 PMC: 11580363. DOI: 10.1186/s12964-024-01941-y.


Versatile Split-and-Mix Liposome PROTAC Platform for Efficient Degradation of Target Protein .

Song C, Jiao Z, Hou Z, Xing Y, Sha X, Wang Y JACS Au. 2024; 4(8):2915-2924.

PMID: 39211615 PMC: 11350581. DOI: 10.1021/jacsau.4c00278.


Function of sildenafil on diseases other than urogenital system: An umbrella review.

Chen Z, Huang Y, Cao D, Qiu S, Chen B, Li J Front Pharmacol. 2023; 14:1033492.

PMID: 36814496 PMC: 9939646. DOI: 10.3389/fphar.2023.1033492.


Identification and validation of four photodynamic therapy related genes inhibiting MAPK and inducing cell cycle alteration in squamous cell carcinoma.

Zhao Y, Dong J, Liao Y, Wang H, Zhou D, Kang J Front Oncol. 2022; 12:946493.

PMID: 35992777 PMC: 9386316. DOI: 10.3389/fonc.2022.946493.


Suppression of mutant Kirsten-RAS (KRAS)-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6.

Kidger A, Saville M, Rushworth L, Davidson J, Stellzig J, Ono M Oncogene. 2022; 41(20):2811-2823.

PMID: 35418690 PMC: 9106580. DOI: 10.1038/s41388-022-02302-0.